Cervix, Phase II
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anca Bulgaru, MD
- Andrea Brennan
- Aparna Kailasam, MD, MBA, MS
- Benjamin Newton, MD
- Blair C. McNamara, MD
- Elena Ratner, MD, MBA
- Justin Persico, MD
- Kathleen Fenn, MD
- Kathleen Pundy
- Katyayani (Katya) Papatla, MD, MPH
- Martha Diaz
- Masoud Azodi, MD
- Megin Iaccarino
- Michelle Greenman, MD, MPH
- Nesrine Khoury
- Peter Dottino, MD, FACOG
- Rebecca Bartomeli
- Robert Legare, MD
- Stephen Lattanzi, MD
- Victoria M. Ettorre, DO, MS
- Last Updated12/18/2025
- Study HIC#2000023639